MDRX — Veradigm Share Price
Last trade - 00:00- $544.95m
- $477.61m
- $594.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.73 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 4.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.88% | ||
| Return on Equity | -31.04% | ||
| Operating Margin | -35.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,502.7 | 1,503.04 | 588.02 | 625.98 | 594.41 | 586.4 | 583.2 | -18.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +36.36 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Veradigm Inc. is a healthcare technology and analytics company. The Company offers platforms, solutions and services that help healthcare provider practices of all sizes and specialties with cloud-based and hosted electronic health record (EHR) platforms, practice management, revenue cycle services, and patient engagement tools. It operates through three segments, which include Provider, Payer, and Life Science. Its Provider business consists of two EHRs, practice management and revenue cycle management, which are patient engagement and enterprise resource planning solutions. Its Payer business delivers solutions that support the end-to-end risk adjustment and quality needs of health plans, spanning analytics, clinical data exchange, provider engagement, and regulatory submissions. Its Life Science Business includes a data and research platform and a commercial media business, which partners with life science and other healthcare companies.
Directors
- Michael Klayko NEC
- Richard Poulton PRE (56)
- Paul Black CEO (63)
- Lisa Khorey EVP (54)
- Tejal Vakharia SVP (48)
- Beth Altman IND
- Mara Aspinall IND (58)
- P. Gregory Garrison IND (67)
- Jonathan Judge IND (67)
- Dave Stevens IND (59)
- David Stevens IND (67)
- Carol Zierhoffer IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 11th, 2000
- Public Since
- July 23rd, 1999
- No. of Shareholders
- 316
- No. of Employees
- 2,300
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 108,990,678
- Address
- 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO, 60654
- Web
- https://veradigm.com
- Phone
- +1 3026587581
- Contact
- Jenny Gelinas
- Auditors
- Grant Thornton LLP
Latest News for MDRX
Upcoming Events for MDRX
Q2 2026 Veradigm Inc Earnings Release
Similar to MDRX
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 06:01 UTC, shares in Veradigm are trading at $5.00. This share price information is delayed by 15 minutes.
Shares in Veradigm last closed at $5.00 and the price had moved by +5.93% over the past 365 days. In terms of relative price strength the Veradigm share price has underperformed the S&P500 Index by -7.55% over the past year.
The overall consensus recommendation for Veradigm is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVeradigm does not currently pay a dividend.
Veradigm does not currently pay a dividend.
Veradigm does not currently pay a dividend.
To buy shares in Veradigm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.00, shares in Veradigm had a market capitalisation of $544.95m.
Here are the trading details for Veradigm:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MDRX
Based on an overall assessment of its quality, value and momentum Veradigm is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Veradigm is $8.00. That is 60% above the last closing price of $5.00.
Analysts covering Veradigm currently have a consensus Earnings Per Share (EPS) forecast of $0.22 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veradigm. Over the past six months, its share price has outperformed the S&P500 Index by +13.23%.
As of the last closing price of $5.00, shares in Veradigm were trading +5.25% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Veradigm PE ratio based on its reported earnings over the past 12 months is 22.73. The shares last closed at $5.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Veradigm's management team is headed by:
- Michael Klayko - NEC
- Richard Poulton - PRE
- Paul Black - CEO
- Lisa Khorey - EVP
- Tejal Vakharia - SVP
- Beth Altman - IND
- Mara Aspinall - IND
- P. Gregory Garrison - IND
- Jonathan Judge - IND
- Dave Stevens - IND
- David Stevens - IND
- Carol Zierhoffer - IND